Literature DB >> 26073330

Alternative splicing as a biomarker and potential target for drug discovery.

Kai-qin Le1, Bellur S Prabhakar2, Wan-jin Hong1, Liang-cheng Li1.   

Abstract

Alternative splicing is a key process of multi-exonic gene expression during pre-mRNA maturation. In this process, particular exons of a gene will be included within or excluded from the final matured mRNA, and the resulting transcripts generate diverse protein isoforms. Recent evidence demonstrates that approximately 95% of human genes with multiple exons undergo alternative splicing during pre-mRNA maturation. Thus, alternative splicing plays a critical role in physiological processes and cell development programs, and.dysregulation of alternative splicing is highly associated with human diseases, such as cancer, diabetes and neurodegenerative diseases. In this review, we discuss the regulation of alternative splicing, examine the relationship between alternative splicing and human diseases, and describe several approaches that modify alternative splicing, which could aid in human disease diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26073330      PMCID: PMC4648177          DOI: 10.1038/aps.2015.43

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  40 in total

1.  A genomic view of alternative splicing.

Authors:  Barmak Modrek; Christopher Lee
Journal:  Nat Genet       Date:  2002-01       Impact factor: 38.330

Review 2.  Pre-mRNA splicing and human disease.

Authors:  Nuno André Faustino; Thomas A Cooper
Journal:  Genes Dev       Date:  2003-02-15       Impact factor: 11.361

Review 3.  Alternative splicing: new insights from global analyses.

Authors:  Benjamin J Blencowe
Journal:  Cell       Date:  2006-07-14       Impact factor: 41.582

Review 4.  The alternative splicing side of cancer.

Authors:  Giuseppe Biamonti; Morena Catillo; Daniela Pignataro; Alessandra Montecucco; Claudia Ghigna
Journal:  Semin Cell Dev Biol       Date:  2014-03-19       Impact factor: 7.727

5.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing.

Authors:  Teresa Rodriguez-Martin; Karen Anthony; Mariano A Garcia-Blanco; S Gary Mansfield; Brian H Anderton; Jean-Marc Gallo
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

6.  An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.

Authors:  A Disset; C F Bourgeois; N Benmalek; M Claustres; J Stevenin; Sylvie Tuffery-Giraud
Journal:  Hum Mol Genet       Date:  2006-02-06       Impact factor: 6.150

7.  Identification of alternative splicing markers for breast cancer.

Authors:  Julian P Venables; Roscoe Klinck; Anne Bramard; Lyna Inkel; Geneviève Dufresne-Martin; ChuShin Koh; Julien Gervais-Bird; Elvy Lapointe; Ulrike Froehlich; Mathieu Durand; Daniel Gendron; Jean-Philippe Brosseau; Philippe Thibault; Jean-Francois Lucier; Karine Tremblay; Panagiotis Prinos; Raymund J Wellinger; Benoit Chabot; Claudine Rancourt; Sherif Abou Elela
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 8.  Genomics of alternative splicing: evolution, development and pathophysiology.

Authors:  Eric R Gamazon; Barbara E Stranger
Journal:  Hum Genet       Date:  2014-01-01       Impact factor: 4.132

9.  Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing.

Authors:  Maayan Salton; Ty C Voss; Tom Misteli
Journal:  Nucleic Acids Res       Date:  2014-11-20       Impact factor: 16.971

10.  Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing.

Authors:  M Ri; E Tashiro; D Oikawa; S Shinjo; M Tokuda; Y Yokouchi; T Narita; A Masaki; A Ito; J Ding; S Kusumoto; T Ishida; H Komatsu; Y Shiotsu; R Ueda; T Iwawaki; M Imoto; S Iida
Journal:  Blood Cancer J       Date:  2012-07-20       Impact factor: 11.037

View more
  34 in total

1.  Precision cancer medicine: where to target?

Authors:  Qiang Yu; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

2.  Systematic evaluation of differential splicing tools for RNA-seq studies.

Authors:  Arfa Mehmood; Asta Laiho; Mikko S Venäläinen; Aidan J McGlinchey; Ning Wang; Laura L Elo
Journal:  Brief Bioinform       Date:  2020-12-01       Impact factor: 11.622

Review 3.  Influence of transcriptional variants on metastasis.

Authors:  Joice De Faria Poloni; Diego Bonatto
Journal:  RNA Biol       Date:  2018-07-24       Impact factor: 4.652

4.  Prognostic alternative splicing signatures and underlying regulatory network in esophageal carcinoma.

Authors:  Zu-Cheng Xie; Hua-Yu Wu; Fu-Chao Ma; Yi-Wu Dang; Zhi-Gang Peng; Hua-Fu Zhou; Gang Chen
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

5.  Identification of personalized neoantigen-based vaccines and immune subtype characteristic analysis of glioblastoma based on abnormal alternative splicing.

Authors:  Zhifang Deng; Peiyan Zhan; Ke Yang; Li Liu; Jue Liu; Wenqi Gao
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

6.  Integrative bioinformatics analysis of prognostic alternative splicing signatures in gastric cancer.

Authors:  Zhen Zong; Hui Li; Zhikun Ning; Cegui Hu; Fuxin Tang; Xiaojian Zhu; Huakai Tian; Taicheng Zhou; He Wang
Journal:  J Gastrointest Oncol       Date:  2020-08

7.  Identification and Characterization of Alternatively Spliced Transcript Isoforms of IRX4 in Prostate Cancer.

Authors:  Achala Fernando; Chamikara Liyanage; Afshin Moradi; Panchadsaram Janaththani; Jyotsna Batra
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

8.  Alternative Splicing of NOX4 in the Failing Human Heart.

Authors:  Zoltán V Varga; Márton Pipicz; Júlia A Baán; Tamás Baranyai; Gábor Koncsos; Przemyslaw Leszek; Mariusz Kuśmierczyk; Fátima Sánchez-Cabo; Pablo García-Pavía; Gábor J Brenner; Zoltán Giricz; Tamás Csont; Luca Mendler; Enrique Lara-Pezzi; Pál Pacher; Péter Ferdinandy
Journal:  Front Physiol       Date:  2017-11-22       Impact factor: 4.566

9.  Identification of prognostic and bone metastasis​-related alternative splicing signatures in mesothelioma.

Authors:  Runzhi Huang; Zixuan Zheng; Sijia Liu; Penghui Yan; Dianwen Song; Huabin Yin; Peng Hu; Xiaolong Zhu; Zhengyan Chang; Yihan Liu; Juanwei Zhuang; Tong Meng; Zongqiang Huang; Jie Zhang
Journal:  Cancer Med       Date:  2021-05-26       Impact factor: 4.452

10.  Computational comparison of common event-based differential splicing tools: practical considerations for laboratory researchers.

Authors:  Ittai B Muller; Stijn Meijers; Peter Kampstra; Steven van Dijk; Michel van Elswijk; Marry Lin; Anna M Wojtuszkiewicz; Gerrit Jansen; Robert de Jonge; Jacqueline Cloos
Journal:  BMC Bioinformatics       Date:  2021-06-26       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.